Lianghui Zhang, MD, PhD

  • Assistant Professor, Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine
  • Assistant Professor, Department of Pharmacology and Chemical Biology
  • Member, Vascular Medicine Institute
  • Member, Center for Vaccine Research

Education & Training

  • Postdoc, University of Illinois at Chicago, 2013-2017
  • PhD in Pharmacology, University of Rochester, 2013
  • MD, Medical School of Fudan University (China), 2003

Research Interest Summary

Immuno-pathogenesis, Vascular biology, Acute lung injury, Virology, Antigen presentation, Signal transduction

Research Interests

My laboratory studies lung vascular biology and immuno-pathogenesis of acute lung injury. Our research focuses on the mechanism of respiratory virus-induced lung vascular injury and signals between endothelial cells and immune cells during the innate and adaptive immune response. The coronavirus and influenza-induced acute lung injury models are two major animal models used in the laboratory. We are also interested in lung vascular regeneration and mechanisms of transcriptional regulation in the vasculature. By understanding the mechanisms which regulate the balance between inflammatory injury and regeneration in viral lung injury, we will be able to develop new therapies that minimize inflammatory injury, maximize tissue repair and reduce patient mortality.


Zhang L*, Narayanan KK, Cooper L, Chan KK, Devlin CA, Aguhob A, Shirley K, Rong L*, Rehman J*, Malik AB*, Procko E*. 2022. An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2. EMBO Molecular Medicine. e16109. 
*: Co-corresponding authorship

Zhang L*, Gao S, White Z, Dai Y, Malik AB, Rehman J*. 2022. Single-Cell Transcriptomic Profiling Identifies Dynamic Inflammatory and Regenerative Subpopulations Following Vascular Injury. JCI Insight. 7: e158079.
*: Co-corresponding authorship

Zhang L*, Dutta S, Xiong S, Chan M, Chan KK, Fan TM, Bailey KL, Lindeblad M, Cooper LM, Rong L, Gugliuzza AF, Shukla D, Procko E*, Rehman J*, Malik AB*. 2022. An engineered high affinity ACE2 peptide therapeutically mitigates lung vascular injury and mortality induced by distinct SARS-CoV-2 variants. Nature Chemical Biology. 18: 342-351.
  *: Co-corresponding authorship

Zhang L, Jambusaria A, Hong Z, Marsboom G, Toth PT, Herbert BS, Malik AB, Rehman J. 2017. SOX17 Regulates Conversion of Human Fibroblasts Into Endothelial Cells and Erythroblasts by Dedifferentiation Into CD34+ Progenitor Cells. Circulation. 135: 2505-2523.

Zhang L, Malik S, Pang J, Wang H, Park KM, Yule DI, Blaxall BC, Smrcka AV. 2013. Phospholipase Cε hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy. Cell. 153: 216-27.

Click here for a full list of publications>